Tango Therapeutics, Inc. (NASDAQ: TNGX)

Tango Therapeutics Inc is a biotechnology company focused on discovering and developing targeted oncology therapies. The company uses synthetic lethality approaches to create drugs that selectively kill cancer cells with specific genetic alterations while sparing normal cells. Its pipeline includes small molecule inhibitors that target methyltransferase PRMT5, the CoREST complex, and the HBS1L protein.

The company currently generates revenue through collaboration and licensing agreements with other pharmaceutical firms. These partnerships provide funding for research development and potential milestone payments. Tango Therapeutics does not yet have commercial product sales.

Tango Therapeutics occupies a niche in the oncology market by focusing on synthetic lethality and biomarker driven patient selection. Its main competitors include large pharmaceutical companies such as AstraZeneca Amgen Bristol Myers Squibb Gilead GlaxoSmithKline Merck KGaA Pfizer Lilly and Roche as well as smaller biotechs like Artios Pharma BeOne Exelixis IDEAYA Biosciences Repare Therapeutics and Servier Pharmaceuticals. The company's competitive advantages stem from its proprietary MTA cooperative mechanism for PRMT5 inhibition its deep understanding of genetic deficiencies and its ability to pair drug candidates with specific patient populations.

The company serves oncology patients who have tumors with defined genetic alterations such as MTAP deletion. Its collaboration partners include Erasca Revolution Medicines and Lilly which provide compound supplies and support clinical trials. These relationships help advance the development of its product candidates toward potential regulatory approval.